Revance Therapeutics Inc (NAS:RVNC)
$ 2.67 -0.04 (-1.48%) Market Cap: 278.88 Mil Enterprise Value: 481.76 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 08:00PM GMT
Release Date Price: $25.15 (+4.66%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good afternoon, everyone. My name is Balaji Prasad. I lead the specialty pharma coverage for Barclays. Thank you for dialing into the Barclays Global Healthcare Conference. Continuing the specialty pharma track of the conference, I'm pleased to introduce the management from Revance today with us. So we have Toby -- Tobin Schilke, whom we all know, Chief Financial Officer. Toby, thank you for taking the time to speak to us today, and I appreciate that you stepped in for Mark, who couldn't attend the conference at the last minute. So thank you again for that especially.

Tobin C. Schilke
Revance Therapeutics, Inc. - CFO & Principal Accounting Officer

Balaji, always appreciate the support, and Barclays is a terrific platform. So thanks, everyone, for your time, and thanks for all the great questions that we're going to go through today.

Questions & Answers

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Fabuluous. So Toby,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot